← Back to Analyst Consensus 
NAUT Buy
Nautilus Biotechnology, Inc.
Current Price —
Implied Upside —
Analysts 10
30-Day Momentum
▲ 1 upgrades / ▼ 0 downgrades / 0 reiterations from 1 firms
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Sep 29, 2026 | Roth Capital | initiate | — → Buy | — | 52% |
| Sep 9, 2026 | Leerink Partners | initiate | — → Outperform | — | 51% |
| Feb 27, 2026 | Guggenheim | maintain | Buy → Buy | $4 | 52% |
| Dec 5, 2024 | Goldman Sachs | downgrade | Neutral → Sell | $1.75 | 54% |
| Jun 27, 2024 | Guggenheim | initiate | — → Buy | $6 | 52% |
| Aug 3, 2023 | Morgan Stanley | reiterate | Equal-Weight → Equal-Weight | $6 | 54% |
| Aug 3, 2022 | Morgan Stanley | maintain | — → Equal-Weight | $6 | 54% |
| Aug 3, 2022 | Goldman Sachs | maintain | — → Neutral | $2 | 54% |
| Jul 14, 2022 | Goldman Sachs | maintain | — → Neutral | $4 | 54% |
| Apr 13, 2022 | Goldman Sachs | maintain | — → Neutral | $5 | 54% |
| Jan 6, 2022 | Morgan Stanley | initiate | — → Equal-Weight | $8 | 54% |
| Nov 2, 2021 | Cowen & Co. | initiate | — → Outperform | $0 | — |
| Aug 4, 2021 | Goldman Sachs | initiate | — → Neutral | $10 | 54% |
| Jul 13, 2021 | Jefferies | initiate | — → Buy | $13 | 51% |
Price Target Trend
Apr 22, 2026 Oct 27, 2026
EPS Estimates
0q —
0y —
+1q —
+1y —
Cross-Platform Signals
No cross-platform signals in the last 90 days